Selection of patient-reported outcome measures in pulmonary arterial

hypertension clinical trials: a systematic review, meta-analysis and health-

related quality of life framework.

Frances Varian[1,2], Rebecca Burney[1,2], Charlotte Pearson[1,2], Ze Ming Goh[1,2], Joseph Newman[3,4],

Gregg Rawlings[5], Hamza Zafar[1,2], David G Kiely[2], AA Roger Thompson[1,2], Robin Condliffe[2], Mark

Toshner[3], Ciara McCormack[6], Iain Armstrong[2,8], Tessa Peasgood[6], Jill Carlton[6], Alex Rothman[1,2]

1. Division of Clinical Medicine, School of Medicine and Population Health, (formerly Faculty

of Medicine, Dentistry and Health), University of Sheffield, Beech hill Rd, Broomhall,

Sheffield, S10 2RX, UK

2. Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching

Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK

3. Royal Papworth Hospital, Papworth Rd, Trumpington, Cambridge, CB2 0AY, UK

4. Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, UK

5. Clinical and Applied Psychology Unit, Cathedral Court, 1 Vicar Lane, Sheffield, S1 2LT,

University of Sheffield, UK

6. Department of Sport Science and Nutrition, Maynooth University, Maynooth, Co. Kildare,

Ireland

7. Sheffield Centre for Health and Related Research (ScHARR), School of Medicine and

Population Health, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1

4DA, UK

8. Pulmonary Hypertension Association United Kingdom, Sheffield, UK

Corresponding author: Alex Rothman

Address: Division of Clinical Medicine, School of Population and Health, Beech Hill Road,
Sheffield, S10 2RX, United Kingdom

Email: a.rothman@sheffield.ac.uk

Conflicting interests

Professor DG Kiely and Dr I Armstrong were involved in the derivation of EmPHasis-10 but remained independent in the risk of bias analysis for the COSMIN review. Professor Jill Carlton is a co-investigator for the UK EQ-5D-5L study team. Dr Tessa Peasgood is a member of EuroQol and involved in research development of the EuroQol Health and Wellbeing instrument. Other authors are not affiliated with PROMs evaluated in this review. The authors (AR/FV/RB/CP/ZMG/JN) performing the data collection, selection and evaluation of review articles have no conflicts of interest.

Funding

Wellcome Trust Clinical Research Career Development Fellowship (AMKR: 206632/Z/17/Z), BHF Intermediate Fellowship (AART: FS/18/13/33281), MRC Experimental Medicine grant (AMKR/MT/DGK: MR/W026279/1), BHF Clinical Research Training Fellowship (HZ/AMKR: FS/CRTF/23/24465, MT/JN: FS/CRTF/22/24390). The research was carried out at the National Institute for Health and Care Research (NIHR) Sheffield and Cambridge cardiorespiratory Biomedical Research Centres. AR is grateful to Richard Hughes, whose generous philanthropic support has helped to make this work possible.

Disclosures

AART research funding: Heart Research UK, Janssen-Cilang Ltd, British Heart Foundation, and honoraria from Janssen-Cilad ltd for lectures and education. **AMKR**: research funding: Wellcome Trust Clinical Research Career Development Fellowship (206632/Z/17/Z), Medical Research Council (UK) Experimental Medicine Award (MR/W026279/1), NIHR Biomedical Research Centre Sheffield, Contribution in kind: Medtronic Inc., Abbott Laboratories, Endotronix Inc., Novartis, Janssen, Merk. Research support and consulting: NXT Biomedical, Endotronix Inc., SoniVie, Neptune, Gradient. **DGK** has received personal funding from the NIHR Biomedical Research Centre Sheffield, research funding from Ferrer, GSK and Janssen and consulting and educational funding from Acceleron, Altivant, Ferrer, Gossamer, Janssen, MSD and United Therapeutics. **FV** has received educational funding from Janssen and is a Medical Research Council (UK) clinical fellow. **JN** Research funding: British Heart Foundation, education and travel funding Aparito Ltd, United Therapeutics. **MT**: Research funding: NIHR Biomedical Research Centre Cambridge, NIHR HTA. Personal support: GSK and Jansen. **RC** has received honoraria for speakers' fees and conference travel from Janssen. All others: none.

Abstract

Introduction

Health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH) is valued as an

outcome measure by patients, clinicians and regulators. The selection of PROMs for

measurement of HRQoL in PAH clinical trials lacks systematic evaluation of their suitability,

accuracy and reliability.

Method

We report a systematic review (PROSPERO ID: CRD42024484021) following PRISMA guidelines

of PROMs selected in PAH clinical trials. PROM measurement properties were then evaluated

according to the ten-step COnsensus-based Standards for the selection of health

Measurement INstruments (COSMIN) checklist and graded by recommendation for use. Finally,

HRQoL was modelled into a conceptual framework using patient interviews and surveys.

Results

Screening of 896 records identified 90 RCTs. 43 trials selected PROMs of which 20 were

sufficiently validated to detect meaningful change. Of these, 8 trials were adequately powered,

using either EQ-5D-5L, SF-36 or the Living with Pulmonary Hypertension Questionnaire (LPHQ).

COSMIN evaluation recommended EmPHasis-10 and LPHQ for use (Grade A), however, SF-36

and EQ-5D-5L require further study (Grade B). A conceptual framework of HRQoL was

developed from literature comprising 8,045 patients. This framework can be used to visualise

the different HRQoL concepts measured by different PROMs.

Conclusion

To improve patient-centred research, greater consistency in PROM selection is required. 3 of 90

RCTs have selected COSMIN-recommended PROMs. Whilst the PROMs evaluated require

development across the ten areas of psychometric property measurement, EmPHasis-10 and

LPHQ can be recommended for use. The ratified conceptual framework can further support

PROM selection by identifying the HRQoL concepts they are likely to capture.

Graphical abstract: selection of patient-reported outcome measures in pulmonary arterial hypertension

clinical trials

COSMIN COnsensus-based standards for the Selection of health-Measurement INstruments,

EQ-5D-5L EuroQol-5D-5L; HRQoL health-related quality of life; LPHQ Living with Pulmonary

Hypertension Questionnaire, MCID minimal clinically important difference; PAH pulmonary

arterial hypertension; PROM patient reported outcome measure, QALY quality-adjusted life

years, RCT randomised controlled trial, SF-36 36-item Short Form survey.

https://BioRender.com/u80x854

Plain language summary (242 of max 300)

Individuals living with pulmonary hypertension want to know which treatments improve their

quality of life related to their health. We use questionnaires to capture the experiences of

people living with pulmonary hypertension. Examples of this used in clinical practice are

EmPHasis-10. We reviewed all the clinical trials in pulmonary hypertension to see which

questionnaires were used to measure health-related quality of life. Some questionnaires may

be better at capturing the experience of living with pulmonary hypertension than others. We

found 20 clinical trials used a questionnaire that could detect a change in health-related quality

of life in pulmonary hypertension. However, only 8 trials were designed to detect a significant

treatment impact. We then evaluated these questionnaires against current best practice

guidelines to ensure they are fit for purpose. EmPHasis-10 and the Living with Pulmonary

Hypertension Questionnaire are preferred from the four evaluated in this study. The final part of

this study was to look at what quality of life means for those living with pulmonary hypertension.

Data from 8045 patients across the world was used to draft a health-related quality of life

framework. We then finalised this design with professionals and patients. This framework can be used in the future to help understand how the well a questionnaire captures things important to those with lived experience of pulmonary hypertension. This will help us to better understand treatments that improve quality of life for people living with pulmonary hypertension.

Background

Endpoints in randomised controlled trials (RCT) have traditionally focussed on physiological measures including functional markers such as 6-minute walk distance (6MWD).[1,2] However, approaches prioritising clinician-derived endpoints [3–5] can undervalue the patient voice. Patient-reported outcome measures (PROMs) are an instrument developed to capture and quantify the experience of living with a health condition. Improvement in health-related quality of life (HRQoL) is an important treatment goal for clinicians, regulators and patients, yet it is often not examined in clinical trials.[6–11] Furthermore, significant advancements in the diagnosis and treatment of pulmonary arterial hypertension (PAH) mean people are living longer, with a focus not only on length of life, but also quality. There are many challenges in validating PROMs for accurate measurement of HRQoL. A ten-step checklist for PROM risk of bias was developed by the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) steering committee.[12] This guidance outlines systematic evaluation of PROMs and facilitates recommendations about PROM suitability.[13,14] This has yet to be undertaken for PROMs in PAH, limiting knowledge of appropriate PROM selection in clinical trials.

PROMs can also be used to evaluate the cost-effectiveness of interventions, typically calculated as Quality Adjusted Life Years (QALYs). To allow such a calculation, PROMs require a value set. Such PROMs are termed a preference-weighted measure (PWM). Value sets are based on the views or preferences of the public and/or patients and vary by country to reflect sociocultural differences.[15,16] A PWM scores each health state described by the PROM as a single value, or 'utility index', on a scale, such that 1 represents full health, and zero represents death. A score below zero indicates a health state considered worse than being dead. The index score of a health state can be combined with time spent in that state to estimate QALYs. QALYs are an important outcome for regulatory and clinical decision-making and therefore dependent upon robust PROMs.[17]

PROM selection in clinical trials should follow guidance developed using international Delphi

approaches (18) and be evidence-based.(14) Condition-specific PROMs may offer greater

sensitivity to changes in HRQoL than generic PROMs, though evidence is limited.(11,19) The

condition-specific PROMs for PAH include the Cambridge Pulmonary Hypertension Outcome

Review (CAMPHOR), EmPHasis-10, Living with Pulmonary Hypertension Questionnaire (LPHQ)

and PAH-SYMptoms and imPACT (PAH-SYMPACT).(20) Guidelines and regulators, such as the

US Food and Drug Administration (FDA), recommend that sensitivity to therapeutic change

must be interpreted as clinically meaningful (defined as the minimal clinically important

difference (MCID)).(11,13,18,21–25) A generic PROM (e.g. SF-36) may be used, providing the

instrument has a MCID validated in the population of interest.(18)(14) MCID interpretation

comprises one of ten-steps evaluating measurement properties within the COSMIN risk of bias

checklist.

We follow the COSMIN systematic review process to facilitate recommendations of which

PROMs should be selected in PAH clinical trials (13,14)(13,14). This process can be further

enhanced by identifying which HRQoL concepts are captured by the PROM.(26) Developing a

conceptual framework aids visualisation of important aspects of HRQoL for people living with

pulmonary hypertension.(27,28) The content of PROMs can then be compared to this

framework to illustrate which aspects of HRQoL are likely to be measured.

Aims and Objectives

This is the first systematic review of PROMs selected for use in clinical trials for adults with

PAH(20,29–31) to, 1) evaluate appropriate selection with a valid MCID, and 2) compare

measurement properties in accordance with the COSMIN checklist, including grading

recommendation for use.(12,14,22–24,32). Additionally, to further inform selection of PROMs,

we undertake a literature review to develop a conceptual framework which summarises the

impact of relevant HRQoL concepts from the perspective of people living with pulmonary

hypertension.

Methods

Systematic searches

The protocol for the systematic review of PAH RCTs was registered on PROSPERO (CRD42024484021). The COSMIN systematic evaluation is not independently registered. Methodology adhered to the Cochrane Handbook of Systematic Reviews of Interventions and COSMIN guidance.(33) Reporting structure followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (see online supplementary figure E1) and PRISMA-COSMIN outcome measurement instruments (online supplementary figure E3 and table E9)(14). MEDLINE (1980 to December 2023) and Cochrane Library (2002 to December 2023) were searched for RCTs evaluating the effectiveness of any clinical intervention in PAH. Inclusion and exclusion criteria are registered on PROSPERO. After removal of duplicates, one author (FV) screened for relevant titles and abstracts before reviewing the full text for eligibility. Where there was uncertainty about the relevance of an article, a second author (JN) reviewed the title and abstract/main text. A third author was available to adjudicate discrepancies. This process was repeated for the PRISMA-COSMIN search strategy and reporting structure (supplementary figure E2 and E3). PRISMA-COSMIN studies included pulmonary hypertension (PH) comprising group 1 and group 4 patients to maximise inclusion of PROM psychometric studies. Forward and backward searches were performed on eligible articles for both searches, and citation searching performed on systematic reviews identified.

Data Extraction

Five authors (FV, RB, CP, ZMG, JN) extracted information independently from all RCTs using a pre-determined template. This included sample and trial characteristics, primary and secondary outcome measures and results, and details of PROMs used.(34)

Risk of Bias and Strength of Evidence

Two authors (ZMG, RB) assessed the systematic review risk of bias using the Cochrane RoB2 Toolkit, and strength of evidence according to the Grading of Recommendations Assessment Development Evaluation (GRADE) criteria. The ten-step COSMIN risk of bias checklist was completed by two authors (FV & CP).(32,33) Any disagreements were discussed until consensus was reached. A COSMIN summary of the overall strength of PROM recommendation is made by grading into one of three categories: (A) PROM can be trusted for use with sufficient evidence of psychometric properties; (B) PROM has potential to be recommended for use but insufficient to meet A or C categories; (C) PROMs with high-quality evidence that a measurement property is insufficient and therefore should not be recommended for use.(12,13,35). A description of psychometric terms is available in supplementary table E5.

Data Analysis

It is recommended that the MCID is considered for sample size calculations for PROM selection.(22–24) To determine whether trials were sufficiently powered for the chosen PROM, the MCID for each instrument was obtained (supplementary table E1). If data were unavailable specifically for PH, an estimated MCID was searched for (1) respiratory conditions and (2) heart failure to maximise PROM inclusion.(29,36–41) GPower v3.1 was used to estimate sample size calculations using the MCID from a two-independent means model for 80% power, 5% significance, one-tailed test. Trials insufficiently powered to detect a meaningful change were excluded.(42,43) Meta-analysis was undertaken per therapy and by PROM in SPSSv28.1.(44)

Conceptual framework and patient and public involvement and engagement (PPIE)

A scoping literature review was conducted independently by two authors (FV & RB) to identify HRQoL concepts in PH.(24,25,45). Published studies using primary and secondary analytical methods and grey literature, such as surveys asked by Pulmonary Hypertension Associations, were included (supplementary table E6).(6–9,46–54) Seven major themes from an a priori model (27,55) were used to inform the conceptual framework. Subthemes were then extracted and grouped.(27,55) Final subthemes were weighted from most to least commonly reported. Key professional stakeholders from centres in the UK and Ireland then ratified the framework followed by PPIE obtained from representatives from Pulmonary Hypertension Association UK (PHA UK) and patient volunteers registered within Sheffield's local PPIE PAH network. Participation was entirely voluntary without reimbursement. The conceptual framework was then used to evaluate the PROMs identified from the COSMIN review in a process called 'mapping', allowing visualisation of which HRQoL concepts are captured by which PROM.

Results

Systematic review of PROMs selected in PAH clinical trials

The systematic search identified 896 unique records. After screening, 178 remained for full-text review. Overall, 90 RCTs were identified and 43 used PROMs as a secondary endpoint (supplementary table E2). All studies showed some risk of bias (supplementary table E3). The strength of all studies using PROMs was 'moderate' (supplementary table E4). There was no reported patient involvement in selection of PROMs in any RCT (supplementary table E2).(18)

MCIDs are available for three of four PH-specific PROMs: EmPHasis-10, LPHQ and CAMPHOR.(29,36,56,57) The MCID for PAH-SYMPACT was excluded as this was in abstract form only with no reported standard deviation.(41,58,59) All available MCID values and methods of derivation are included in supplementary table E1. Figure 1 shows that 20 of the 43 RCTs selected a PROM with an MCID for PAH. Of these, only 8 trials met the full inclusion criteria with adequate power to detect a meaningful change in HRQoL (Table 1).(60–103) PROMs meeting final inclusion (Table 1) were SF-36, EQ-5D-5L, LPHQ and Minnesota Living with Heart Failure-PH (MLWHF-PH). A utility index is available for use of EQ-5D-5L as a PWM for the PAH population(3), but not a specific MCID. The MCID from an interstitial lung disease population was therefore used as a surrogate estimation for sample size to maximise inclusivity.(104)

Bosentan (EARLY)(90)), IV epoprostenol (PACES)(92), and inhaled treprostinil (TRIUMPH-I)(89) did not meet their primary endpoint (6MWD) which was consistent with findings of no improvement in the SF-36 physical functioning domain (Table 1). Significant improvements in 6MWD for ambrisentan (ARIES2)(105) and exercise (EU-TRAIN-01)(106) were reported, however only the MCID was met for the role-physical domain of SF-36 in EU-TRAIN-01(106).

PATENT-1(107) and PATENT-2(108) (riociguat vs placebo) were the only RCTs available for meta-analysis (Figure 2). Two PROMs (EQ-5D-5L and LPHQ) were completed by the same patients. EQ-5D-5L overall appeared less responsive to changes in HRQoL (Cohen's d ES=0.24, SE=0.08, p<0.001) compared to LPHQ (ES=-0.48, SE=0.11, p<0.001) (Figure 2). Though an exploratory endpoint, it is unclear which country-specific value sets were used for EQ-5D-5L, limiting meaningful interpretation as a PWM.(16,109–112) All trials reported statistical significance (p<0.05) between arms rather than following regulatory recommendations of interpreting results in the context of the MCID. A sustained improvement in HRQoL is shown with all dose-regimes of riociguat compared to placebo, as measured by LPHQ.(108) However EQ-5D-5L was only responsive to change in the 1.5mg subgroup and not the 2.5mg (Figure 2).(113)(108) On further examination, the 1.5mg subgroup had a statistically higher proportion of patients in WHO FC III compared to II (Fisher's exact p<0.05), supporting the need for evaluation of psychometric property performance. (108)

For COSMIN evaluation, 369 eligible articles were screened with additional citation searching (n=20) from 3 systematic reviews. EmPHasis-10 was considered relevant for inclusion due to

available MCID and selection in two recruiting RCTs with adequate sample size.(114,115) 21

studies demonstrated measurement properties (supplementary figure E3).(20,36,43,56,116–

132) MLWHF for Pulmonary Hypertension (MLWHF-PH)(117) was later renamed LPHQ and

therefore these instruments are pooled for evaluation.(20,36,116,117) SF-36 is available as

both a PWM and PROM. However, the MCID for SF-36 is only available for four of eight domains

(physical functioning, role-physical, energy-fatigue and social functioning).(119) EQ-5D-5L is

also a PWM with a value-set for PH,(133)(36) though no specific MCID is available and there are

few psychometric studies. All PROMs selected from the initial systematic review of clinical

trials were included in step ten of the checklist which evaluates PROM

responsiveness.(12,13,32,35)

PROM suitability for the PAH population: reporting the ten-step COSMIN checklist

Steps 1 and 2 of the COSMIN risk of bias assessment involves evaluation of PROM development

and consideration of how comprehensively a PROM measures HRQoL in PAH. This is described

as content validity. Additional descriptions of COSMIN psychometric terms are in

supplementary table E5. COSMIN measurement properties of selected PROMs are outlined in

Table 2 with full details in supplementary tables E7 and E8.

COSMIN recommends that pre- and post- cognitive interviewing with patients and experts must

be performed to adequately validate PROM content (steps 1 and 2). LPHQ was the only

instrument to satisfy this criteria. No post-hoc cognitive interviewing has been performed in the

PAH population for SF-36, EmPHasis-10 or EQ-5D-5L and content validation for these PROMs is

therefore insufficient (Table 2).

COSMIN steps 3,4 and 5 outline the appropriate sample sizes and tests in which to evaluate the

internal structure of the PROM (i.e. how well the questionnaire items perform in measuring

HRQoL). The *structural validity (step 3)* should be appropriately analysed and reported as an

overall 'model fit'.(134) The type of model helps determine PROM scoring. LPHQ is a

multidimensional model with three scoring methods: physical, emotional and total scores.(36)

SF-36 is also multidimensional with eight domains and physical and mental component scores,

whereas EmPHasis-10 was derived as a unidimensional structure (i.e. a single, total

score).(122) However, a recent model analysis restructured EmPHasis-10 into three scoring

components: breathlessness, fatigue and independence.(128) Further clinical evaluation is

required. Overall, *structural validity* is not reported for SF-36 or EQ-5D-5L and is inadequate for

LPHQ and EmPHasis-10 (Table 2).

Additional checks for internal structure include, step 4 – *internal consistency:* to evaluate

whether similar concepts agree, (typically Cronbach's alpha ≥0.7), and step 5 – *measurement*

invariance: stability of PROM responses across different groups (i.e. reducing potential

confounders e.g. age, gender). *Internal consistency* is sufficient for LPHQ, EmPHasis-10 and

SF-36. This property is not relevant for EQ-5D-5L as items are not inter-related (i.e. they all

measure different concepts), with only 1 item per domain (Table 2).(135) No studies adequately

considered *measurement invariance* (step 5).(123) Step 5 additionally involves evaluation of

cross-cultural validity. To use PROMs in multiple different languages and cultures, appropriate

statistical testing must be performed.(12,14) While multiple translations are available for EQ-

5D-5L and SF-36, there is insufficient validation in the PAH population (Table 2, online

supplementary table E8).(136) However, EmPHasis-10 demonstrates strong linguistic

testing.(125,126,130,137) Developed in the UK and Ireland, EmPHasis-10 is the only PROM

validated in the US, China, Japan, Italy and Turkey.(122,123,125,126,129,130) LPHQ is available

in English only, though was developed in the US, France and Germany.

Step 6 evaluates PROM performance under stable conditions, termed *test-retest reliability,* e.g.

the intraclass correlation coefficient. This ensures reproducible PROM scores under similar

conditions. Reliability should be interpreted within the context of step 7 – *measurement error*

e.g. standard error of measurement (SEM). *Measurement error* defines the natural score

variation of responders during a period of stability. If the mean variation exceeds the MCID

(clinical interpretation of the score), then the PROM becomes invalid, as any detectable change

is indistinguishable from normal scoring variation. According to COSMIN, this would raise a

major bias concern, rendering the PROM as grade C – not recommended for use.(12,14) Test-

retest reliability is sufficient for EmPHasis-10 and indeterminate for LPHQ due to limited

evaluation of measurement error (supplementary table E8). Only two SF-36 domains (physical

functioning and general health) meet adequate test-retest reliability. Other domains have a high

risk of bias due to wide confidence intervals and SEM.(118,119)

Criterion validity (step 8) can be used to assess sensitivity and specificity of the instrument;

however, this requires a 'gold standard' measure/PROM and is therefore excluded from this

analysis. Step 9 – *Hypothesis testing,* should occur in a stable population and consider 1) how

well the PROM correlates with other PROMs developed for PAH (*convergent validity*), 2) how

well the PROM discriminates known subgroups e.g. WHO FC (*construct validity*). Correlation

with other PAH-specific PROMs is satisfactory for LPHQ, EmPHasis-10 and SF-36, and

indeterminate for EQ-5D-5L (supplementary table 8). LPHQ and EmPHasis-10 both show good

correlation with WHO FC,(36,116,131) though SF-36 is inadequate.(43,116,119,132) In-hospital

invasive haemodynamic assessments have yet to show strong correlation with any

PROM.(43,113,114,118–120,124)

Step 10 evaluates responsiveness. Again, described as a *construct approach*, this considers 1)

the responsiveness of the PROM with the responsiveness of other PROMs (as exemplified in

Figure 2), 2) ability to detect changes in subgroups, and 3) response to an intervention (Table 2,

Figure 2). EmPHasis-10 and LPHQ show satisfactory subgroup responsivity (e.g. improvement

from WHO FC III to II) (supplementary table E8). EmPHasis-10 is historically absent from RCT

interventions, with much-anticipated trials underway.(56,122,123,127).

Summary COSMIN instrument recommendations are grade A for LPHQ and EmPHasis-10 and

grade B for SF-36 and EQ-5D-5L. No PROMs received a grade C recommendation. However, the

overall quality of evidence for LPHQ and Emphasis-10 is low, and for SF-36 very low (Table 2).

Developing a HRQoL conceptual framework for PROM content validation

Improving HRQoL matters to people living with pulmonary hypertension. Surveys report this as

the most important treatment focus (52-83%) over other outcomes such as life expectancy (33-

75%, n=1196, UK, Canada).(10,46) HRQoL concepts of interest may vary between clinical and

trial applications,(24,32,45,138) however, recognising their relationship to PROMs is key for

appropriate selection. A conceptual framework developed from the Wilson and Cleary – and

subsequent – models(27,28,55) was inductively modified to reflect concepts of HRQoL. These

subthemes (e.g. 'stigma') were identified from combined questionnaires and surveys of 8,045

people living with pulmonary hypertension globally.(19,123,139) Demographics (where

available) were reflective of the disease prevalence with a female predominance (79%,

n=4,700). Average age of patients was 55 years (range 24-80 years) and 88% self-reported to be

Caucasian (supplementary table E6).

Figure 3A summarises the conceptual framework, with six themes and 25 subthemes

identified. The framework was ratified by 6 PH consultants, 2 clinical fellows, 1 clinical nurse

specialist, 1 physiotherapist, and 1 clinical psychologist, and PPIE obtained from two PHA UK

representatives and five patients with relevant demographic representation. No additional

themes or subthemes were identified.

The most frequently reported concepts in Figure 3A are presented in bold, with most-to-least

common left-to-right and those overlapping having similar weighting. The most reported

impacts were activity, sadness/depression, self-worth, sense of loss, treatment- and financial

burden. Cultural variation was evident for this latter subtheme and more commonly discussed

in surveys and interviews of those living in Canada, USA and China compared the UK and

Europe.

PROM content was then 'mapped' onto the conceptual framework (Figure 3B) to visualise

themes and subthemes likely to be measured. No single PROM covers all subthemes directly.

EmPHasis-10 and LPHQ cover all main themes. Two commonly reported themes, self-identity

and autonomy, are not specifically captured by EQ-5D-5L or SF-36. In addition, EQ-5D-5L does

not capture the impact of PAH on relationships. LPHQ is the only PROM to directly ask about

treatment burden by including items on side effects, but may also include items that are less

impactful in this patient group (e.g. diet).

Discussion

This is the first systematic review to evaluate meaningful changes in HRQoL in RCTs in patients

with PAH. Based on rigorous methodology using COSMIN guidance, both EmPHasis-10 and

LPHQ receive a grade A recommendation for use, whereas SF-36 and EQ-5D-5L receive a grade

B recommendation. Of these PROMs EmPHasis-10 provides the broadest scope internationally

and is validated on three continents. PROMs meeting COSMIN guidance meet historical FDA

recommendations,(11) however this regulatory guidance pre-dates international Delphi

consensus.(13,14,18) Whilst SF-36 is the most frequently used PROM in PAH RCTs to date, 6 of

8 SF-36 domains are insufficiently evidenced according to the checklist. No PROMs selected in

PAH RCTs to date are adequate for PAH-QALY calculation. All ten areas of the checklist require

further study, as the overall quality of evidence summary is low or very low.

To aid future PROM selection and HRQoL evaluation, we developed a conceptual framework which allows visualisation of aspects of HRQoL important to people living with PAH. Six themes and 25 subthemes were identified by researchers and ratified in the conceptual framework. Whereas both EmPHasis-10 and LPHQ likely capture all major themes, two major themes (self-identity and autonomy) are unlikely to be captured by SF-36 and EQ-5D-5L. Further cognitive interviewing discussing how PROMs relate to this conceptual framework from the patients' perspective is required.

Selection of PROMs should be clinically meaningful and patient-centred

PROMs should be resilient to the day-to-day variability in HRQoL. There will be a natural change in score, without a significant change in HRQoL, and this may vary depending on disease severity. Meaningful change in HRQoL, therefore, may not equate to statistical difference.(140,141) It is common practice in PAH to calculate meaningful change thresholds on clinician-derived concepts, or by asking patients to report change using the SF-36 physical functioning domain and compare this to functional changes using 6MWD.(142) Caution is advised when interpreting these MCID values, as they capture a narrow view of HRQoL, as illustrated by multiple concepts of the HRQoL framework.(142,143) PAH-SYMPACT outlined responder thresholds in a recent abstract, calculating the MCID using clinician-derived measures (6MWD, haemodynamics and WHO FC).(59) On review of the COSMIN guidance, this would be considered hypothesis testing/responsiveness (steps 9 and 10), rather than a patient-centred change in HRQoL. CAMPHOR remains the only PROM in PAH to include patient opinion in derivation of a MCID, however the feasibility of using this 65-item questionnaire in clinical trials has potentially limited historical selection.(56,142,144) There is further inaccuracy caused by over-simplifying the MCID at the group-level.(140,145) Multiple MCIDs should ideally be anchored over many individual timepoints to improve sensitivity.(140,142,143) Other factors influencing MCID include direction of change (improvement or deterioration) and individual baseline value, none of which are available for the PAH PROMs evaluated.(145) While highly valuable for trial endpoints, MCIDs should be interpreted with caution, and within the context of measurement error to determine true change over natural responder variability.(21,140,142,145)

HRQoL is a complex construct to accurately measure

HRQoL is a multifactorial construct with diurnal, daily and lifelong variability. Perception varies across the patient's lifespan. Changes in values and priorities (*response shift*) depends upon whether patients are 'pre-diagnosis', 'transitioning through diagnosis' or 'duration living with PH'. The latter group reportedly face challenges with recognising disease progression and monitoring the condition.(51,146) Registry data shows consistent performance of EmPHasis-10 in patients with recent diagnoses (<6 months) but other time points are lacking, with further research required.(123)

Further complexity is introduced by variations in HRQoL perceptions with age, gender, and disease severity.(147) Age and gender have been shown to influence PROMs.(138,148) These factors require further assessment in the PAH population.(122,139,148,149) Perceptions and response to limitations in activity also vary with individual coping strategies and personality types**.**(146) Responses may therefore differ depending on the choice of PROM. No PROMs used in PAH trials have specifically addressed variations in activity perceptions in longitudinal subgroup analyses. Consideration of stability and changes across subgroups (steps 9 and 10) is also required (e.g. WHO FC).(140) As shown by the meta-analysis, EQ-5D-5L may be less responsive to changes in WHO FC II compared to WHO FC III, potentially underestimating the HRQoL treatment benefit in this subgroup. Similar responses were shown when comparing EQ-5D-5L with CAMPHOR.(150) Combining PROMs in a trial setting provides useful comparators of responsiveness and is recommended for psychometric evaluation.(12,14)

Development of the conceptual framework helps visualise important HRQoL concepts captured by PROMs. All PROMs capture limitations in activities, however two major themes identified (self-identity and autonomy) are unlikely to be captured by SF-36 and EQ-5D-5L (Figure 3B). While LPHQ has received critique for poor symptom saturation,(29,36) concepts such as 'time in hospital' and 'side effects' are uniquely captured. Some symptoms may be less relevant. For example, 'palpitations', 'problems with limbs', and 'diet' were not reported as commonly impactful in the HRQoL framework.(6–9,36,46–52) However, LPHQ is also the only instrument to consider financial impact, which may have cultural relevance.(7,9,47,49) It is unclear whether PROMs adequately capture treatment burden (a key subtheme) in PAH, or whether this cross-loads (i.e. is captured elsewhere) with other concepts. Future cognitive interviewing is required to validate all PROMs reviewed. This should consider utilising the conceptual framework to elicit patient interpretation of PROMs, and identifying perceptions of

themes and subthemes across the disease course. 'Mapping' the content of PROMs to the

concepts in this HRQoL framework will also help to solidify PROM content validity.

Future selection of PROMs in PAH clinical trials

PROMs offer a descriptor for the patient voice, and allow for patient-centred research. This

requires appropriate PROM selection with a patient-centred MCID, and prioritisation of PPIE

preferences which are reported in line with recommendations.(18,151–156) Greater

consistency in PROM selection will improve knowledge of therapeutic outcomes according to

lived patient experience. As a minimum, PAH clinical trials should select PROMs with grade A

recommendation for use. PROMs may also offer further value in health economic evaluation,

though neither generic PWM (EQ-5D-5L and SF-36) can be recommended at this time.(150,157)

CAMPHOR(158) is currently the only condition-specific PWM with a value set, however, this is

underutilised in RCTs and yet to undergo COSMIN evaluation. Future development of PWMs in

PAH should focus on either improving PROMs with a B grade recommendation and/or

developing a value set for those with a grade A recommendation. This will support robust

evaluation for QALY outcomes.

Strengths and Limitations

Our systematic review of recent publications was designed with rigour, using multiple

reviewers, a minimum of dual coders, and triangulation to enhance quality. Nevertheless, data

informing the conceptual framework was not analysed at source and therefore may be subject

to bias. However, following UK PPIE opinion, there were no additional concepts added to the

framework and, based on the authors experience in international studies in PAH, we consider

the framework to be relevant for other countries. As with adaptation of PROMs cross-culturally,

future research is required to ensure individual concepts are applicable to the chosen area.

This process could offer further understanding of cultural differences in people living with PAH.

Analysis of instrument power was based on MCID; although, as discussed, this may be

inadequate, potentially over- or under-estimating the RCTs included.(21) However, this is

currently the only available measurement criteria for estimating sufficient responsiveness, and

useful for calculating study size.(12,13,35) CAMPHOR has an MCID but did not meet inclusion

due to insufficiently powered historical or forthcoming RCTs. As this is currently the only PAH-
specific PWM,(150,158) independent COSMIN analysis is warranted. Finally, it is recognised
that all PROMs considered in this analysis were developed prior to COSMIN guideline
recommendations, and therefore some of the methodological concerns may be overstated due
to missing publication details rather than instrument flaws. Despite these challenges and low
quality of evidence, two instruments still achieved a grade A recommendation and should be
prioritised for selection in future PAH clinical trials.
534
535 **Conclusion**
536
Eight PAH clinical trials were adequately powered to detect a meaningful change in HRQoL.
Only three of these trials selected PROMs recommended for use. Despite their low grade of
evidence, both LPHQ and EmPHasis-10 can be recommended for use in clinical trials. SF-36
and EQ-5D-5L should be used with caution without further examination. Combining these with
a grade A recommended PROM may be useful, in addition to offering potential for health
economic analyses. The gaps in evidence highlighted using the COSMIN ten-step checklist
should be consulted for future psychometric development. These include cognitive interviewing
to strengthen content validity, evaluation of natural score variability and further MCID
validation, taking into consideration the patient voice, directionality and disease severity.
Selection of PROMs internationally also needs to consider cultural validity, which is not
necessarily concordant with language availability. PROM selection can be further supported
using the ratified conceptual framework to identify the HRQoL concepts they are likely to
capture.

Study	N=	Demographics (Age (y), Female (%))		Intervention	PROM[†]	Additional Endpoints	Primary outcome met?
		Control	Therapy				
EU-TRAIN-01 (2021)(106)	129	55±12.7 77.6%	52.3±12.4 69%	Exercise training	SF-36 (all)	*Primary* 6MWD *Secondary* WHO FC, CPET	Yes
PATENT-2 (2015) (113,159)	396	49±16 80%	49±16 80%	Riociguat	LPHQ EQ-5D-5L	*Primary* 6MWD *Secondary* CWE, NTProBNP, WHO FC, haemodynamics	Yes
PATENT-1 (2013)(160)	443	51±17 78%	51±17 79%	Riociguat	LPHQ EQ-5D-5L	*Primary* 6MWD *Secondary* CWE, NTProBNP, WHO FC, haemodynamics	Yes
TRIUMPH-I (2010)(161)	235	52(18-75) 82%	55(20-75) 81%	Inhaled Treprostinil	MLWHF-PH	*Primary* 6MWD	No
EARLY(2008) (162)	185	44±17 63%	45±18 76%	Bosentan	SF-36 (all)	*Primary* 6MWD, PVR *Secondary* CWE, NTProBNP, haemodynamics	No
ARIES2 (2008)(105)	394	51±14 68%	51±15 78%	Ambrisentan	SF-36 (physical)	*Primary* 6MWD *Secondary* CWE	Yes
PACES (2008) (163)	267	48±13 77%	48±13 82%	Sildenafil + IV Epoprostenol	SF-36 (all)	*Primary* 6MWD	No
AIR (2002)(164)	203	53±12 68%	51±13 68%	Inhaled Iloprost	EQ-5D-5L and EQ-VAS	*Primary* 6MWD *Secondary* NYHA, PVR, CWE	Yes

Table 1. Characteristics of studies powered for HRQoL

6MWD six-minute walk distance, CPET cardiopulmonary exercise test, CWE clinical worsening events, EQ (EuroQoL)-5D-5L, EQ-VAS EuroQoL visual analogue scale, HRQoL health-related quality of life, NTProBNP N-terminal Pro-Brain Natriuretic Peptide, NYHA New York Heart Failure Association functional score, PROM patient-reported outcome measure, PVR pulmonary vascular resistance, WHO FC World Health Organisation Functional Class

[†]All secondary endpoints

Figure 1: HRQoL Instruments in PAH RCTs from systematic review categorised by ability to distinguish meaningful change in the PAH population.

20 of 43 trials selected an instrument with a MCID for HRQoL. 56 total instruments are included as 13 trials included more than one instrument, see supplementary table E2 for all RCTs with a HRQoL endpoint. No trials reported results in the context of MCID. PAH-SYMPACT MCID evaluation is underway.(59)

BDI Beck's depression inventory, CAMPHOR Cambridge Pulmonary Hypertension Outcome Review, E10 EmPHasis-10, EuroQol(EQ)-5D-5L, DFI dyspnoea fatigue index, FSS fatigue severity score, HADS hospital anxiety and depression questionnaire, HAP human activity profile , IPAQ International Physical Activity Questionnaire, KCCQ Kansas City Cardiomyopathy Questionnaire, LPHQ Living with Pulmonary Hypertension Questionnaire, MCID minimal clinically important difference. MLWHF Minnesota Living with Heart Failure, NHP Nottingham Health Profile, PAH-SYMPACT pulmonary arterial hypertension symptoms and impact questionnaire, PGA patient global assessment, SF-36 Short-Form-36, SGA subject global assessment.

Figure 2: Meta-analysis of HRQoL outcomes for riociguat

PROM instruments LPHQ (A) and EuroQoL (EQ)-5D-5L (B). 1.5mg dose in Patent-1 for LPHQ was excluded as subgroup insufficiently powered. HRQoL health-related quality of life, LPHQ Living with Pulmonary Hypertension. Utility index score was not reported with EQ-5D-5L analysis. PROMs delivered at start and week 12 for PATENT-1, and every 2 weeks up to week 8 for PATENT-2 follow-on study. 12-month follow-up data for EQ-5D-5L from PATENT-2 not included. No imputation reported of missing data. *2.5mg riociguat 2013,*(111) *n= 254 (WHO FC III, n = 140 (55%) Vs WHO FC II, n = 108 (43%)** p>0.05; riociguat 1.5mg 2013, n =63 (WHO FC III, n= 39 (62%) Vs WHO FC II, n = 19 (30%)***p<0.0001); 2.5mg riociguat 2015,*(108) *n= 231 (WHO FC III, n= 127 (55%) Vs WHO FC II, n=97 (42%)** p>0.05; 1.5mg riociguat 2015, n = 56 (WHO FC III n= 35(63%) Vs WHO FC II, n =17 (30%)** p<0.005 all Fisher's exact test.*

Figure 3: (LEFT) Conceptual framework for PAH HRQoL and (RIGHT) Example of 'mapping' of PROMs used in PAH RCTs onto the conceptual framework.

[LEFT] Framework of patient-reported themes (n=6) and subthemes (n=25) identified by two independent reviewers on impact of pulmonary hypertension (majority group 1 PAH) on HRQoL . Directly reported concepts are in bold (n= 8045 from supplementary table E6). Concepts may indirectly cross subthemes (cross loading), for example, treatment burden may impact on the EQ-5D-5L item

'pain/discomfort' as a reflection of treatment side effects however this is not included within the scope of this analysis. Further PROMs mapped are available in online supplementary figure E4.(114) LPHQ is combined with MLWHF as instruments are identical. [RIGHT] Conceptual mapping of PROMs to HRQoL framework (undertaken by 6 PH consultants, 2 PH clinical fellows, 1 nurse specialist, 1 clinical psychologist, 1 physiotherapist). LPHQ covers all main themes compared to EQ-5D-5L. EQ-5D-5L EuroQol-5D-5L, LPHQ Living with Pulmonary Hypertension Questionnaire, MLWHF Minnesota Living with Heart Failure, PWM preference-weighted measure, SOB shortness of breath, SF-36 Short-Form 36.

		LPHQ/MLWHF (36,107,108,116,117,131)	EmPHasis-10 (56,122–126,128–130,165)	SF-36 (43,106,116–121,162–164,166)	EQ-5D-5L (36,113,160,167)
Characteristics	Setting	Clinical & Trial	Clinical	Clinical	NA
	Completion	5-10 min	3-4 min	5-10 min	3-4 min
	Number of Items / scales	21 Likert	10 Likert	36 Likert/ discrete	5 Likert
	Recall period	One week	Recent experience	Varies with item	Today
	Derivation PAH	US, Germany, France	UK & Ireland	NA	NA
	Translations	English	>20(137)	193	208
	Cost***	Free(168)	Free(169)	Free(170)	Free(171)
	Construct(s)	Total, Physical & Emotional summary scores	Total score	8 Domains*, Physical & Mental scores	Score indexed for population health state
	Scoring / (Best HRQoL)	0-105 (0)	0-50 (0)	Varies	0-1 (1)
Content validity (steps 1-2)	1.Construct	+	+	-	NA
	1.Concept	?	-	-	NA
	1.Cognitive Interview	?	-	-	NA
	2.Patients	+	?	-	NA
	2.Experts	-	?	-	NA
Internal Structure (steps 3-5)	3.Structural validity	?	?	NA	NA
	4.Internal consistency	+	+	+	■
	5.Measurement invariance/ cross-cultural validity	NA/ none	- US, Japan, China, Italy, Turkey	NA/ None for PH[†]	NA/ None for PH[†]
Reliability (steps 6-7)	6. Test-retest	?	+	?	NA
	7.Measurement error	-	+	+	NA
Hypothesis Testing (steps 8-10)	8. Criterion validity	NA	NA	NA	NA
	9. Convergent/ construct validity	+	+	+	?
	10. Response to intervention	+	NA	+	?
	10.Subgroup responsivity	+	+	?[≠]	NA
Quality of Evidence Summary		Low	Low	Very Low	NA
Recommendation (A to C)		A	A	B	B

Table 2: Summary of PROM characteristics, measurement properties and evidence quality

sufficient (+), insufficient (–), or indeterminate (?), (NA) not available. Summary of evidence quality based on a modified GRADE approach. Properties with moderate to high evidence quality are shaded grey. Recommendations are made by three categories (A) PROM can be trusted for use with evidence for sufficient content validity and internal consistency, (B) potential to be recommended for use but not categorized as A or C or (C) PROMs with high quality evidence that a measurement property is insufficient and therefore should not be recommended for use.

***non-commercial use, *8 items: P physical, RP role physical, EF energy fatigue, SF social functioning, MH mental health, RE role emotional, GH general health, V vitality. Factor coefficients for mental and physical summary scores are held under copyright, reporting a total overall score is not recommended.(118,172) ⚡inconsistencies with item functioning. Full summary of findings available in online supplement tables E7 and E8. †cross-cultural validation may be available for other disease areas/healthy populations however this is outside the scope of this search. If further evaluation is undertaken for measurement invariance in the PAH population, it is recommended to re-evaluate availability cross-culturally.

GRADE Grading of Recommendations Assessment Development Evaluation, EuroQol-5D-5L (EQ-5D-5L), LPHQ Living with Pulmonary Hypertension Questionnaire, MLWHF Minnesota Living with Heart Failure, SF Short Form-36

Contributions

All authors contributed to the development of the manuscript and approved the final version

Acknowledgements

The authors would like to thank the patients from PHA UK and PHA UK representatives who supported the ratification of the conceptual framework. Thank you to Dr Charlie Eliot for ratifying the conceptual framework in addition to the authors.

Statement of Guarantor

N/A

Contact emails and ORCID

f.varian@sheffield.ac.uk	0000-0002-4644-8391
joseph.newman@nhs.net	0000-0001-5514-0754
charlotte.pearson21@nhs.net	0009-0005-8120-9678
R.Thompson@sheffield.ac.uk	0000-0002-0717-4551
gregg.rawlings@sheffield.ac.uk	0000-0002-7916-9313.
a.rothman@sheffield.ac.uk	0000-0002-7847-4500
ciara.a.mccormack@mu.ie	0000-0003-4508-5522
rebecca.burney@nhs.net	0009-0001-4984-6029
T.Peasgood@sheffield.ac.uk	0000-0001-8024-7801
zmgoh13@gmail.com	0000-0001-8912-8470
j.carlton@sheffield.ac.uk	0000-0002-9373-7663

References

1. Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, et al. The evolving landscape of pulmonary arterial hypertension clinical trials. The Lancet [Internet]. 2022 Nov 26 [cited 2022 Dec 13];400(10366):1884–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36436527

2. Sitbon O, Nikkho S, Benza R, Deng C (CQ), Farber HW, Gomberg-Maitland M, et al. Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulm Circ. 2020 Oct;10(4):1–11.

3. Nafees B, de Freitas HM, Beaudet A, Todd E, Gin-Sing W. A Health State Utility Study to Elicit Societal Values Associated with Pulmonary Hypertension. Patient Prefer Adherence. 2023 Aug;Volume 17:2119–30.

4. Dong W, Zhang Z, Chu M, Gu P, Hu M, Liu L, et al. Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension. Front Pharmacol. 2023 Aug 11;14.

5. Ekhlasi M, Sheikhi S, Majd ZK, Peiravian F, Yousefi N. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran. Value Health Reg Issues. 2023 Mar;34:78–85.

6. Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: Patients' experiences. Heart & Lung. 2005 Mar;34(2):99–107.

7. Guillevin L, Armstrong I, Aldrighetti R, Howard LS, Ryftenius H, Fischer A, et al. Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives. European Respiratory Review. 2013 Dec 1;22(130):535–42.

8. PHA UK. What it means to live with PH today [Internet]. 2017 [cited 2023 Oct 5]. Available from: https://www.phauk.org/research-survey-work/living-ph-report/

9. Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med. 2019 Dec 21;19(1):67.

10. Tremblay É, Gosselin C, Mai V, Lajoie AC, Kilo R, Weatherald J, et al. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation. 2022 Aug 23;146(8):597–612.

11. Fda. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.

12. Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, et al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Quality of Life Research. 2018 May 19;27(5):1171–9.

13. Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Quality of Life Research. 2018 May 17;27(5):1159–70.

14. Elsman EBM, Mokkink LB, Terwee CB, Beaton D, Gagnier JJ, Tricco AC, et al. Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024. Health Qual Life Outcomes. 2024 Jul 9;22(1):48.

15. Nancy Devlin KSYFBM and B van H. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England [Internet]. 2016 [cited 2024 Feb 18]. Available from: https://www.ohe.org/wp-content/uploads/2016/04/25-Jan-OHE-research-paper_value-set-paper-CORRECTED.pdf

16. Gerlinger C, Bamber L, Leverkus F, Schwenke C, Haberland C, Schmidt G, et al. Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results. BMC Res Notes. 2019 Dec 14;12(1):18.

17. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010 Dec 1;96(1):5–21.

18. Prinsen CAC, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a 'core outcome set.' Trials. 2014 Dec 25;15(1):247.

19. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618–731.

20. Yarlas A, Mathai SC, Nathan SD, DuBrock HM, Morland K, Anderson N, et al. Considerations When Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients With Pulmonary Hypertension. Chest. 2022 Nov;162(5):1163–75.

21. United States Food and Drug Administration. PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE PUBLIC WORKSHOP Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments [Internet]. 2018 [cited 2024 Jul 15]. Available from: https://www.fda.gov/media/116277/download

22. Lapin BR. Considerations for Reporting and Reviewing Studies Including Health-Related Quality of Life. Chest. 2020 Jul;158(1):S49–56.

23. Leidy NK, Revicki DA, Genesté B. Recommendations for Evaluating the Validity of Quality of Life Claims for Labeling and Promotion. Value in Health. 1999 Mar;2(2):113–27.

24. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols. JAMA. 2018 Feb 6;319(5):483.

25. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used

in patient-centered outcomes and comparative effectiveness research. Quality of Life Research. 2013 Oct 4;22(8):1889–905.

26.   Finch AP, Brazier JE, Mukuria C. What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews. The European Journal of Health Economics. 2018 May 30;19(4):557–70.

27.   Wilson IB. Linking Clinical Variables With Health-Related Quality of Life. JAMA. 1995 Jan 4;273(1):59.

28.   McDool E, Carlton J, Powell PA, Coates E, Knox L, Mayberry E, et al. Measuring Health-Related Quality of Life in Amyotrophic Lateral Sclerosis. Neurology. 2024 Jul 23;103(2).

29.   Rose SW, Highland KB, Kelkar AA. Clinical Utility of Patient-Reported Outcome Instruments in the Management of Pulmonary Hypertension. JACC Heart Fail. 2024 Feb;12(2):366–76.

30.   Chen H, Taichman DB, Doyle RL. Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension. Proc Am Thorac Soc. 2008 Jul 15;5(5):623–30.

31.   Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. Chest. 2014 Sep;146(3):686–708.

32.   Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Quality of Life Research. 2018 May 12;27(5):1147–57.

33.   COSMIN. Guideline for Systematic Reviews of Outcome Measurement Instruments [Internet]. Amsterdam; 2020 Dec [cited 2023 Jun 1]. Available from: Guideline for Systematic Reviews of Outcome Measurement Instruments

34.   U.S. Food and Drug Administration (FDA). Surrogate Endpoint Resources for Drug and Biologic Development [Internet]. 2018 [cited 2024 May 24]. Available from: https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development

35.   Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Quality of Life Research. 2018 May 12;27(5):1147–57.

36.   Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes. 2013;11(1):161.

37.   Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, et al. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res. 2019 Dec 1;20(1):47.

38.   Gonzalez-Saenz de Tejada M, Bilbao A, Ansola L, Quirós R, García-Perez L, Navarro G, et al. Responsiveness and minimal clinically important difference of

the Minnesota living with heart failure questionnaire. Health Qual Life Outcomes. 2019 Dec 14;17(1):36.

39. Butler J, Shahzeb Khan M, Lindenfeld J, Abraham WT, Savarese G, Salsali A, et al. Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. JACC Heart Fail. 2022 Sep;10(9):651–61.

40. McClure NS, Sayah F Al, Xie F, Luo N, Johnson JA. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value in Health. 2017 Apr;20(4):644–50.

41. Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, et al. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest. 2018 Oct 1;154(4):848–61.

42. Ulrich S. A Further Step Toward Meaningful Trial Outcomes for Patients with Pulmonary Arterial Hypertension: Minimal Important Difference in 6-minute-walk Distance. Am J Respir Crit Care Med. 2023 Apr 15;207(8):972–4.

43. Taichman DB, Shin J, Hud L, Archer-Chicko C, Kaplan S, Sager JS, et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res. 2005 Dec 10;6(1):92.

44. Peasgood T, Brazier J. Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values? Pharmacoeconomics. 2015 Nov 2;33(11):1101–5.

45. Aiyegbusi OL, Nair D, Peipert JD, Schick-Makaroff K, Mucsi I. A narrative review of current evidence supporting the implementation of electronic patient-reported outcome measures in the management of chronic diseases. Ther Adv Chronic Dis. 2021 Jan 24;12:204062232110159.

46. PHA UK. Breathless not voiceless: what it means to live with pulmonary hypertension today [Internet]. 2023 [cited 2024 Apr 2]. Available from: https://www.phauk.org/research/pha-uk-led-research/breathless-not-voiceless-what-it-means-to-live-with-ph-today/

47. Péloquin J, Robichaud-Ekstrand S, Pepin J. Quality of life perception by women suffering from stage III or IV primary pulmonary hypertension and receiving prostacyclin treatment. Can J Nurs Res. 1998;30(1):113–36.

48. Yorke J, Armstrong I, Bundock S. Impact of living with pulmonary hypertension: A qualitative exploration. Nurs Health Sci. 2014 Dec 15;16(4):454–60.

49. Zhai Z, Zhou X, Zhang S, Xie W, Wan J, Kuang T, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers. Medicine. 2017 Sep;96(39):e6783.

50. McDonough A, Matura LA, Carroll DL. Symptom Experience of Pulmonary Arterial Hypertension Patients. Clin Nurs Res. 2011 May 3;20(2):120–34.

51. PHA UK. Helping people get the most from their PH treatments: Phoenix study proposal findings [Internet]. 2021 [cited 2023 Jul 18]. Available from: https://www.phauk.org/app/uploads/2021/04/Phoenix-study-research-report.pdf

52. Newman J, Armstrong I, PHA UK. https://www.phauk.org/clinical-trials-what-matters-to-you/. 2022 [cited 2024 Apr 2]. Clinical trials: what matters to you. Available from: https://www.phauk.org/clinical-trials-what-matters-to-you/

53. McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The importance of patient perspectives in pulmonary hypertension. European Respiratory Journal. 2019 Jan;53(1):1801919.

54. Rawlings GH, Beail N, Armstrong I, Condliffe R, Kiely DG, Sabroe I, et al. Adults' experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies. BMJ Open. 2020 Dec 7;10(12):e041428.

55. Brazier J, Peasgood T, Mukuria C, Marten O, Kreimeier S, Luo N, et al. The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results. Value in Health. 2022 Apr;25(4):482–91.

56. Hendriks PM, van Thor MCJ, Wapenaar M, Chandoesing P, van den Toorn LM, van den Bosch AE, et al. The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Med. 2021 Sep 1;186:106525.

57. Bunclark K, Doughty N, Michael A, Abraham N, Ali S, Cannon JE, et al. A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. Pulm Circ. 2021;11(2):2045894021995055.

58. McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, et al. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016 Dec 14;17(1):72.

59. K. Benjamin JPFWGTGBM and DRRamey. Evaluation of Responder Thresholds for PAH-SYMPACT Domain Scores in Patients With Sotatercept Treatment in the STELLAR Study (abstract). . In: American Thoracic Society International Conference Abstracts > D102 HOT TOPICS IN BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH. 2024.

60. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin V V., et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2023 Apr 20;388(16):1478–90.

61. Howard LS, Rosenkranz S, Frantz RP, Hemnes AR, Pfister T, Hsu Schmitz SF, et al. Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE). Chest. 2023;163(2).

62. Ozcan Kahraman B, Tanriverdi A, Savci S, Odaman H, Akdeniz B, Sevinc C, et al. Effects of Inspiratory Muscle Training in Patients With Pulmonary Hypertension. Am J Cardiol. 2023 Sep;203:406–13.

63. Rosenkranz S, Feldman J, McLaughlin V V, Rischard F, Lange TJ, White RJ, et al. Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2022 Jan;10(1):35–46.

64. Grünig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: Results from a large European multicentre randomized controlled trial. Eur Heart J. 2021;42(23).

65. Hemnes AR, Silverman-Lloyd LG, Huang S, MacKinnon G, Annis J, Whitmore CS, et al. A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension. Chest. 2021;160(3).

66. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2021 Apr 1;384(13):1204–15.

67. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021 Jun;9(6):573–84.

68. Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grünig E, et al. Three-Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021 Oct;78(14):1393–403.

69. Aslan GK, Akıncı B, Yeldan I, Okumus G. A randomized controlled trial on inspiratory muscle training in pulmonary hypertension: Effects on respiratory functions, functional exercise capacity, physical activity, and quality of life. Heart & Lung. 2020 Jul;49(4):381–7.

70. Kahraman BO, Savci S, Ozsoy I, Baran A, Acar S, Ozpelit E, et al. Effects of neuromuscular electrical stimulation in patients with pulmonary arterial hypertension: a randomized controlled pilot study. J Cardiol. 2020 Jun;75(6):702–8.

71. Yılmaz BC, Güçlü MB, Keleş MN, Taçoy GA, Çengel A. Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension. Heart and Lung. 2020;49(5).

72. McLaughlin V V., Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, et al. Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. The Journal of Heart and Lung Transplantation. 2019 Dec;38(12):1286–95.

73. Babu AS, Padmakumar R, Nayak K, Shetty R, Mohapatra AK, Maiya AG. Effects of home-based exercise training on functional outcomes and quality of life in patients with pulmonary hypertension: A randomized clinical trial. Indian Heart J. 2019;71(2).

74. Gerhardt F, Dumitrescu D, Gärtner C, Beccard R, Viethen T, Kramer T, et al. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: A randomised clinical study. Heart. 2017;103(8).

75. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study). Chest. 2013 Sep;144(3):952–8.

76. van Campen JSJA, de Boer K, van de Veerdonk MC, van der Bruggen CEE, Allaart CP, Raijmakers PG, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. European Respiratory Journal. 2016 Sep;48(3):787–96.

77. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2015 Dec 24;373(26):2522–33.

78. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013 Jul 25;369(4):330–40.

79. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal. 2015 May;45(5):1303–13.

80. Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. European Respiratory Journal. 2015 May;45(5):1314–22.

81. Saglam M, Arikan H, Vardar-Yagli N, Calik-Kutukcu E, Inal-Ince D, Savci S, et al. Inspiratory Muscle Training in Pulmonary Arterial Hypertension. J Cardiopulm Rehabil Prev. 2015 May;35(3):198–206.

82. Ulrich S, Keusch S, Hildenbrand FF, Lo Cascio C, Huber LC, Tanner FC, et al. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. Eur Heart J. 2015 Mar 7;36(10):615–23.

83. Chan L, Chin LMK, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA, et al. Benefits of Intensive Treadmill Exercise Training on Cardiorespiratory Function and Quality of Life in Patients With Pulmonary Hypertension. Chest. 2013 Feb;143(2):333–43.

84. Weinstein AA, Chin LMK, Keyser RE, Kennedy M, Nathan SD, Woolstenhulme JG, et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med. 2013;107(5).

85. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation. 2013 Mar 12;127(10):1128–38.

86. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study). Chest. 2012 Dec;142(6):1383–90.

87. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, et al. Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension. Circulation. 2011 Jun 28;123(25):2985–93.

88. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171–7.

89. McLaughlin V V., Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2010 May;55(18):1915–22.

90. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet. 2008 Jun;371(9630):2093–100.

91. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 2008 Jun 10;117(23):3010–9.

92. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21;149(8):521–30.

93. Hoeper MM. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. European Respiratory Journal. 2006 Oct 1;28(4):691–4.

94. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. Circulation. 2006 Oct 3;114(14):1482–9.

95. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2005 Aug;46(3):529–35.

96. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292–7.

97. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004 Sep;24(3):353–9.

98. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun;41(12):2119–25.

99. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine. 2002 Aug;347(5):322–9.

100. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. New England Journal of Medicine. 1996 Feb;334(5):296–301.

101. Farha S, Saygin D, Park MM, Cheong HI, Asosingh K, Comhair SAA, et al. Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. JCI Insight. 2017 Aug 17;2(16).

102. Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, et al. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Respir Care. 2017 Apr;62(4):489–96.

103. Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, et al. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. Chest. 2017 Jan;151(1):106–18.

104. Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, et al. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2021 Jan;76(1):37–43.

105. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 2008 Jun 10;117(23):3010–9.

106. Grünig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: Results from a large European multicentre randomized controlled trial. Eur Heart J. 2021;42(23).

107. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013 Jul 25;369(4):330–40.

108. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal. 2015 May;45(5):1303–13.

109. Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med. 2016 May;4(5):361–71.

110. Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. European Respiratory Journal. 2015 May;45(5):1314–22.

111. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013 Jul 25;369(4):330–40.

112. Xie F, Pickard AS, Krabbe PFM, Revicki D, Viney R, Devlin N, et al. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). Pharmacoeconomics. 2015 Aug 31;33(8):867–77.

113. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal. 2015 May;45(5):1303–13.

114. Varian F, Dick J, Battersby C, Roman S, Ablott J, Watson L, et al. Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies. Pulm Circ. 2024 Jan 17;14(1).

115. Deliu N, DR, MA, SJ, DM, JR, WM, TM, VS. StratosPHere 2: A response-adaptive randomised placebo-controlled Phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2. pre-print. 2023;

116. Chua R, Keogh AM, Byth K, O'Loughlin A. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J. 2006 Nov 13;36(11):705–10.

117. Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med. 2008 Oct;102(10):1431–8.

118. Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L'amri M, Gain K, et al. Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension. BMC Pulm Med. 2013 Dec 12;13(1):45.

119. Gilbert C, Brown MCJ, Cappelleri JC, Carlsson M, McKenna SP. Estimating a Minimally Important Difference in Pulmonary Arterial Hypertension Following Treatment With Sildenafil. Chest. 2009 Jan;135(1):137–42.

120. Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP. United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). The Journal of Heart and Lung Transplantation. 2008 Jan;27(1):124–30.

121. Li JL, Xiao F, Liu HT, Li HT, Zhao QH, Sun CY, et al. Long-term outcomes in health-related quality of life influence chronic disease management in patients with pulmonary hypertension. Front Cardiovasc Med. 2022 Nov 10;9.

122. Yorke J, Corris P, Gaine S, Gibbs JSR, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. European Respiratory Journal. 2014 Apr 1;43(4):1106–13.

123. Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, et al. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. European Respiratory Journal. 2021 Feb;57(2):2000414.

124. Favoccia C, Kempny A, Yorke J, Armstrong I, Price LC, McCabe C, et al. EmPHasis-10 score for the assessment of quality of life in various types of pulmonary hypertension and its relation to outcome. Eur J Prev Cardiol. 2019 Aug 19;26(12):1338–40.

125. Takeyasu R, Tamura Y, Abe K, Goda A, Satoh T, Suda R, et al. Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertension　— Multicenter Study in Japan —. Circ Rep. 2020 Apr 10;2(4):255–9.

126. Shi Y, Dong X, Hu X, Weng L, Liu Y, Lai J, et al. Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification. BMC Pulm Med. 2022 Dec 5;22(1):264.

127. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A, et al. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal. 2021 Feb;57(2):2000124.

128. Rawlings GH, Gaskell C, Beail N, Thompson A, Armstrong I. Exploratory and confirmatory factor analysis of emPHasis-10: The health-related quality-of-life measure in pulmonary hypertension. Pulm Circ. 2024 Apr 12;14(2).

129. Odevoglu P, Demir R, Okumus G, Kucukoglu MS, Kuran Aslan G. Validity and reliability of the Turkish version of the EmPHasis-10 questionnaire in patients with pulmonary hypertension. J Eval Clin Pract. 2019 Oct 22;25(5):896–902.

130. Surace A, Torre R, Di Simone E, Dionisi S, Giannetta N, Di Muzio M. Studio di validazione dell'emPHasis-10 per la popolazione italiana. Nsc Nursing. 2019 May 6;1(1):1–18.

131. Cenedese E. Measurement of quality of life in pulmonary hypertension and its significance. European Respiratory Journal. 2006 Oct 1;28(4):808–15.

132. Fernandes CJ, Martins BC, Jardim CV, Ciconelli RM, Morinaga LK, Breda AP, et al. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcomes. 2014 Dec 30;12(1):130.

133. Davies EW, Llewellyn S, Beaudet A, Kosmas CE, Gin-Sing W, Doll HA. Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. Patient Prefer Adherence. 2018 Jun;Volume 12:1079–88.

134. Mokkink LB PCPDAJBL de VHTC. COSMIN methodology for systematic reviews of Patient-Reported Outcome Measures (PROMs) user manual Version 1.0 [Internet]. 2018 [cited 2024 May 30]. Available from: https://cosmin.nl/wp-content/uploads/COSMIN-syst-review-for-PROMs-manual_version-1_feb-2018.pdf

135. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Quality of Life Research. 2021 Mar 7;30(3):647–73.

136. Alagappan T. The cross-cultural adaptation process of a patient-reported outcome measure. Journal of the Scientific Society. 2023;50(1):13.

137. Foster E, Guillen A, Lara K, Oh P, Popielnicki A, Walker G, et al. Linguistic Validation of The Emphasis-10 Questionnaire: A Patient-Reported Outcome Instrument For Assessing Qol In Pulmonary Hypertension (Ph). Value in Health. 2015 Nov;18(7):A744.

138. Calvert MJ, Cruz Rivera S, Retzer A, Hughes SE, Campbell L, Molony-Oates B, et al. Patient reported outcome assessment must be inclusive and equitable. Nat Med. 2022 Jun 5;28(6):1120–4.

139. Mair KM, Johansen AKZ, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014 Feb 13;171(3):567–79.

140. Hays RD, Peipert JD. Between-group minimally important change versus individual treatment responders. Quality of Life Research. 2021 Oct 15;30(10):2765–72.

141. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 9;11(2):171–84.

142. Swigris J, Foster B, Johnson N. Determining and reporting minimal important change for patient-reported outcome instruments in pulmonary medicine. European Respiratory Journal. 2022 Oct;60(4):2200717.

143. Devji T, Carrasco-Labra A, Qasim A, Phillips M, Johnston BC, Devasenapathy N, et al. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. BMJ. 2020 Jun 4;m1714.

144. Bunclark K, Doughty N, Michael A, Abraham N, Ali S, Cannon JE, et al. A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. Pulm Circ. 2021 Apr;11(2):1–9.

145. Hays RD, Woolley JM. The Concept of Clinically Meaningful Difference in Health-Related Quality of Life Research. Pharmacoeconomics. 2000 Nov;18(5):419–23.

146. Kingman M, Hinzmann B, Sweet O, Vachiéry JL. Living with pulmonary hypertension: unique insights from an international ethnographic study. BMJ Open. 2014 May;4(5):e004735.

147. Rawlings GH, Beail N, Armstrong I, Condliffe R, Kiely DG, Sabroe I, et al. Adults' experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies. BMJ Open. 2020 Dec 7;10(12):e041428.

148. Hertler C, Seiler A, Gramatzki D, Schettle M, Blum D. Sex-specific and gender-specific aspects in patient-reported outcomes. ESMO Open. 2020;5:e000837.

149. F. Salaffi MCACSGWG. A comparison of utility measurements using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011;661–71.

150. McKenna SP, Ratcliffe J, Meads DM, Brazier JE. Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes. 2008 Dec 21;6(1):65.

151. Bours MJL. Moving towards increased implementation of evidence-based measurements through comprehensive and transparent reporting: the PRISMA–COSMIN 2024 reporting guideline. Quality of Life Research. 2024 Aug 9;33(8):2047–8.

152. Terwee CB, Ahmed S, Alhasani R, Alonso J, Bartlett SJ, Chaplin JE, et al. Comparable Real-World Patient-Reported Outcomes Data Across Health Conditions, Settings, and Countries: The PROMIS International Collaboration. NEJM Catal. 2024 Aug 21;5(9).

153. U.S. Department of Health and Human Services Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making [Internet]. 2023 Apr [cited 2024 Oct 14]. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.fda.gov/media/166830/download

154. Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018 Nov;Volume 9:353–67.

155. Snyder C, Crossnohere N, King M, Reeve BB, Bottomley A, Calvert M, et al. The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials. Clinical Trials. 2022 Jun 31;19(3):277–84.

156. Crossnohere NL, Brundage M, Calvert MJ, King M, Reeve BB, Thorner E, et al. International guidance on the selection of patient-reported outcome measures in clinical trials: a review. Quality of Life Research. 2021 Jan 14;30(1):21–40.

157. National Institute for Health and Care Excellence. NICE health technology evaluations: the manual (PMG36) [Internet]. 2022 Jan [cited 2024 Jul 15]. Available from: https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741

158. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, et al. The responsiveness and validity of the CAMPHOR Utility Index. European Respiratory Journal. 2008 Dec 1;32(6):1513–9.

159. Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. European Respiratory Journal. 2015 May;45(5):1314–22.

160. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013 Jul 25;369(4):330–40.

161. McLaughlin V V., Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2010 May;55(18):1915–22.

162. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet. 2008 Jun;371(9630):2093–100.

163. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21;149(8):521–30.

164. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine. 2002 Aug;347(5):322–9.

165. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A, et al. EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal. 2021 Feb;57(2):2000124.

166. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 2008 Jun 10;117(23):3010–9.

167. EuroQol Research Foundation. EQ-5D-5L User Guide [Internet]. 2019 Sep [cited 2024 Apr 15]. Available from: https://euroqol.org/wp-content/uploads/2023/11/EQ-5D-5LUserguide-23-07.pdf

168. University of Minnesota. Living with Pulmonary Hypertension Questionnaire (LPHQ) [Internet]. 2024 [cited 2024 Aug 1]. Available from:

https://license.umn.edu/product/living-with-pulmonary-hypertension-questionnaire-lphq

169. PHA UK. EmPHasis-10 Questionnaire [Internet]. 2024 [cited 2024 Aug 1]. Available from: https://www.phauk.org/pha-uk-resources/emphasis-10-questionnaire/#:~:text=The%20EmPHasis%2D10%20questionnaire%20is,patients%20during%20remote%20assessments%20only.

170. QualityMetric. The SF-36v2® Health Survey [Internet]. 2024 [cited 2024 Aug 1]. Available from: https://www.qualitymetric.com/health-surveys/the-sf-36v2-health-survey/

171. EuroQol. How to obtain EQ-5D [Internet]. 2024 [cited 2024 Aug 1]. Available from: https://euroqol.org/register/obtain-eq-5d/how-to-obtain-eq-5d/#:~:text=The%20EuroQol%20user%20license%20policy,public%20health%2C%20and%20similar%20purposes.

172. Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016 Jan 1;4:205031211667172.

Selection of Patient-Reported Outcome Measures in Pulmonary Arterial Hypertension Trials

PROSPERO ID: CRD42024484021

1. **Inclusion criteria**: Randomised Controlled Trials (RCTs) powered for minimal clinically important difference (MCID) of PROM
2. **COSMIN** evaluation of PROM psychometric measurement properties

A Recommended
B Further evaluation needed
C Not recommended

Systematic Review of Selected Patient Reported Outcome Measures (PROMs)

- 90 RCTs
- 43 HRQoL endpoint
- 20 PAH MCID
- 8 Powered
- 1 Meta-Analysis
- 3 Selected Recommended PROMs

COnsensus based standards for Selection of health-Measurement INstruments (COSMIN) recommendations for use

A EmPHasis-10, LPHQ — 4 PROMs — SF-36, EQ-5D-5L **B**

- ✗ Not all SF-36 domains reliable
- ✗ No PAH-specific psychometric testing for EQ-5D-5L

- ○ EQ-5D-5L less responsive than LPHQ
- ○ COSMIN-recommended PROMs should be selected in future trials
- ○ Further research required for generic PROMs & QALY estimates

CONCEPTUAL FRAMEWORK

8045 patients — Themes identified — Framework ratified

Ratified HRQoL framework used to map PROM concepts of interest

FUTURE FOCUS
Results of the 10-step COSMIN checklist should guide future development of PROMs for use in PAH clinical trials

Themes	Subthemes
Feelings & Emotions	Sadness, Depression — Anxiety — Isolation — Fear and Uncertainty — Anger — Frustration
Self-identity	Self-worth
Autonomy	Sense of Loss

Concepts of HRQoL not captured by EQ-5D-5L or SF-36

Relationships	Sexual Relationship — Friends & Family — Stigma/'Hidden' illness — Clinical relationship
Physical	Treatment burden — Fatigue — Breathlessness — Dizziness — Headache — Sleep
Activity	Financial Impact — Daily variability — Travel — Hospital visits — Work/Education — Returning to activities — Public places

Most Commonly Reported → **Less Commonly Reported**